Synonym
PROPIZEPINE; PROPIEZEPINE, (±)-; (±)-PROPIEZEPINE; UP 106; VAGRAN 50
IUPAC/Chemical Name
6-(2-(dimethylamino)propyl)-6,11-dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-5-one
InChi Key
YFLBETLXDPBWTD-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H20N4O/c1-12(20(2)3)11-21-15-9-5-4-8-14(15)19-16-13(17(21)22)7-6-10-18-16/h4-10,12H,11H2,1-3H3,(H,18,19)
SMILES Code
CC(CN1C2=C(NC3=C(C=CC=N3)C1=O)C=CC=C2)N(C)C
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
296.37
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kopanski C, Türck M, Schultz JE. Effects of long-term treatment of rats with antidepressants on adrenergic-receptor sensitivity in cerebral cortex: Structure activity study. Neurochem Int. 1983;5(5):649-59. doi: 10.1016/0197-0186(83)90059-1. PMID: 20487994.
2: Kamal A, Reddy KL, Devaiah V, Shankaraiah N, Reddy DR. Recent advances in the solid-phase combinatorial synthetic strategies for the benzodiazepine based privileged structures. Mini Rev Med Chem. 2006 Jan;6(1):53-69. doi: 10.2174/138955706775197875. PMID: 16457632.
3: Rajagopalan R, Bandyopadhyaya A, Rajagopalan DR, Rajagopalan P. The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds. Bioorg Med Chem Lett. 2014 Jan 15;24(2):576-9. doi: 10.1016/j.bmcl.2013.12.024. Epub 2013 Dec 11. PMID: 24365159.
4: Ellenbroek BA, Liégeois JF, Bruhwyler J, Cools AR. Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. J Pharmacol Exp Ther. 2001 Jul;298(1):386-91. PMID: 11408566.
5: Dereux JF. Le Vagran 50: un antidépresseur situationnel [Vagran 50: a situational antidepressant]. Sem Hop Ther. 1976 Sep-Oct;52(7-8):385-8. French. PMID: 996559.
6: Shi F, Xu X, Zheng L, Dang Q, Bai X. Method development for a pyridobenzodiazepine library with multiple diversification points. J Comb Chem. 2008 Mar-Apr;10(2):158-61. doi: 10.1021/cc7002039. Epub 2008 Feb 9. PMID: 18260649.
7: Lwoff JM, Larousse C, Simon P, Boissier JR. Profil psychopharmacologique d'un antidépresseur potentiel appartenant à la série pyridobenzodiazépine [Psychopharmacological pattern of a potential antidepressive drug of the pyridobenzodiazepine series]. Therapie. 1971 May-Jun;26(3):451-7. French. PMID: 5113799.
